Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy
| Autor: | William H. Morrison, David I. Rosenthal, Renata Ferrarotto, Jack Phan, Nikhil G. Thaker, Ehab Y. Hanna, C. David Fuller, Pamela K. Allen, Bhavana V. Chapman, G. Brandon Gunn, Dario Pasalic, Steven J. Frank, Bonnie S. Glisson, Adam S. Garden, Ethan B. Ludmir, Shirley Y. Su, Jay Reddy |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Interquartile range Neoplasms Physicians Internal medicine Proton Therapy Clinical endpoint Humans Medicine Radiology Nuclear Medicine and imaging Patient Reported Outcome Measures Prospective Studies Prospective cohort study MD Anderson Dysphagia Inventory Feeding tube business.industry Minimal clinically important difference Common Terminology Criteria for Adverse Events Hematology Treatment Outcome Oncology 030220 oncology & carcinogenesis Cohort business |
| Zdroj: | Radiotherapy and Oncology. 148:258-266 |
| ISSN: | 0167-8140 |
| DOI: | 10.1016/j.radonc.2020.05.007 |
| Popis: | Background and purpose To report physician-assessed toxicities (PATs) and patient-reported outcomes (PROs) in a prospective cohort of patients treated using proton beam therapy (PBT). Methods and materials From 2011 to 2019, PBT-treated patients with a sinonasal malignancy were enrolled with a primary endpoint of toxicity assessment. PATs and PROs were assessed at baseline, acute (during PBT), subacute (within 90 days after PBT), and chronic time points. PATs were graded with the Common Terminology Criteria for Adverse Events V4.0. PROs were assessed with the Xerostomia-Related Quality-of-Life Scale (XeQoLS), MD Anderson Dysphagia Inventory (MDADI), and Functional Assessment of Cancer Therapy (FACT). PRO changes from baseline to follow-up were defined as significantly different based on a paired t-test plus a minimal clinically important difference. Results Sixty-four patients had a median follow-up time of 33 months (interquartile range: 10–52 months). The most common histology was olfactory neuroblastoma (28%) and most patients had T4 disease (46%). One acute G3 neurologic PAT (blurred vision) resolved, and no late G3–4 neurologic PATs were observed. Feeding tube placement occurred in 6% of patients. No significant changes were noted in PROs from baseline to the chronic period. Significant worsening from baseline was noted in the XeQoLS acute-subacute physical functioning, pain, personal/psychological distress, and social function; acute-subacute MDADI physical function; and acute-subacute FACT head/neck subscale. The 3-year local control, disease-free survival, and overall survival rates were 88%, 76%, and 82%, respectively. Conclusions We demonstrate low grade ≥3 toxicity and encouraging disease outcomes with PBT. PROs suggest significant changes in the acute-subacute period but no chronic sequelae. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect